Cadila Healthcare Ltd (Zydus Cadila) on Tuesday said it has received final approval from the USFDA for Bupropion Hydrochloride Extended-release Tablets USP (XL) in the strength of 300 mg.
The drug falls in the anti-depressant segment, according to a company release here.
The estimated sales in 2013, as per IMS, for this product was $255.9 million. The total market for Bupropion was estimated at $526.7 million.
The group now has 87 approvals and has so far filed 216 ANDAs since the start of filing process in FY 2003-04.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.